The GenAI effect: Redefining the pharma landscape

Generative AI (GenAI) has the potential to disrupt the pharma industry, from drug development to commercial functions. The general perception is that these digital capabilities are essential for evolving operations and improving patient outcomes. As spending on AI and digital transformation continues to rise globally, the pharma sector is poised for its next wave of disruption.

However, despite GenAI becoming a buzzword in recent years, life sciences companies are implementing it at different speeds. And companies have often faced challenging ethical, regulatory and operational questions.

For example, how can you adjust your data strategy to enable the full potential of GenAI? In which areas is pharma first going to be able to use GenAI to its full potential? What are the best practices regarding integrating GenAI into operations?

Join us for this provocative Open Mic event as we navigate the future of pharma, questioning whether GenAI is the next big leap forward or simply a passing trend. Engage with experts and discover how to strategically position your organization in the evolving landscape of pharma innovation.

Program

16:00 -Door opening

16:30 - Welcome by hosts Ursula Costa, Director DayOne – Healthcare Innovation, Basel Area Business & Innovation
Rahel Schneider, Community Manager and Site Development, Switzerland Innovation Park Basel Area

16:35 – Keynote by Petra Jantzer, Global Lifesciences Lead, Accenture

16:55 - Discussion with the key opinion leaders
Roche panelist, to be announced soon, Roche
Kathrin Schwan, ASG Data & AI Lead, Accenture
Michael Moor, Assistant Professor for Medical AI, ETH Zurich
Nikita Popov, Head of AI Strategy Office, Novartis

17:40 - Q&A session

18:00 - Apéro